Mepolizumab 100 mg vs placebo
Moderate‐to‐severe exacerbations (rate) · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg showed no clear difference in rate of moderate or severe exacerbations All participants compared with placebo (moderate certainty).
1 finding from 1 review
- Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes onlyRate ratio 0.92 [0.82, 1.03]2 studies · 1285 participantsModerate